Mucinex DM 12 Hour Max Strength Expectorant & Cough Medicine, Excess Mucus Relief, FSA, 28 Tablets

Are you searching for reliable cold and cough medicine for adults? Look no further than Maximum Strength Mucinex DM 12hr Expectorant & Cough Suppressant. Featuring a robust 1200 mg of guaifenesin and 60 mg dextromethorphan HBr, this top-notch chest congestion and cough medicine is here to provide effective symptom relief from bothersome excess mucus and persistent cough. When the cold and flu season hits, trust Mucinex for cough and cold symptom relief for adults. Our original bi-layer tablet provides immediate and extended-release and lasts up to 12 hours.
COUGH & COLD MEDICINE FOR ADULTS: Maximum Strength Mucinex DM 12 hr expectorant & cough suppressant packs a powerful punch with 60 mg dextromethorphan HBr & 1200 mg guaifenesin extended release tablets
EXCESS MUCUS RELIEF: Maximum Strength Mucinex DM 12hr provides relief for your chest congestion & cough, makes coughs more productive, & lasts up to 12 hours
EXPECTORANT FOR ADULTS: Maximum Strength Mucinex DM helps clear lungs of excess mucus and phlegm; Say goodbye to chest congestion and cough, say hello to excess mucus relief with our original bi-layer tablets
EXTENDED RELEASE GUAIFENESIN & DEXTROMETHORPHAN HBr: Experience long-lasting symptom relief with Maximum Strength Mucinex DM 12 hr extended-release 1200 mg guaifenesin and 60 mg dextromethorphan HBr tablets
TRUSTED BRAND: Mucinex is the #1 Cough & Cold Brand Doctor's Trust* and is also the #1 Pharmacist Recommended OTC Expectorant**; Get the brand that doctors trust and recommend
COLD AND FLU MEDICINE FOR ADULTS: For powerful cough, cold, and flu multi-symptom relief, check out our range of Mucinex Fast-Max cold and flu medicines; Beat cold and flu symptoms with confidence
FSA & HSA Eligible: Save Up to 30%; Cover out-of-pocket expenses with pre-tax dollars; Product eligibility may vary by plan - Check with your benefits administrator to determine which expenses are eligible before you shop
*IQVIA using ProVoice Survey, August 2023; **U.S. News & World Report/Pharmacy Times 2023-2024